ECB Eyes Rate Hike Amid Iran Conflict-Driven Energy Price Surge 
Global Flight Cancellations 2026: Middle East Air Travel Chaos Explained 
U.S. Oil Prices Slide as Middle East Ceasefire Talks Spark Market Optimism 
Bank of Japan Officials Signal Continued Interest Rate Hikes Amid Inflation Concerns 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Oil Prices Plunge Over 6% as Middle East Ceasefire Hopes Ease Supply Fears 
Wall Street Slides as Iran War Uncertainty, Oil Surge, and AI Fears Rattle Markets 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Explosion and Fire Erupt at Valero Oil Refinery in Port Arthur, Texas 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Moderna Inc. enters a historic $1 billion deal with China to research, develop, and produce exclusive mRNA medicines in the country. The agreement, announced amid growing Sino-American tensions, signifies Beijing's increasing openness to foreign pharmaceutical involvement.
The Cambridge, Massachusetts-based pharmaceutical and biotechnology company announced the new deal with Chinese officials on Wednesday, July 5. The agreement is for Moderna to research, develop and produce messenger RNA medicines in the country.
CNBC noted that an agreement was reached despite the growing tensions between China and the United States. Moderna and Beijing signed a memorandum of understanding (MOU) and land collaboration deal to develop drugs that will be made "exclusively for the Chinese people." This means the two sides agreed that the new drug would never be exported and remain in China.
A local media publication reported earlier this week that Moderna is set to invest about $1 billion in the project. It was added that Moderna's chief executive officer, Stephane Bancel, is set to visit Shanghai, possibly to talk more about the deal and for facility inspection.
"These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," the company's spokesman stated.
In a separate statement that was sent to Yahoo Finance, Moderna said, "We signed a memorandum of understanding and a related land collaboration agreement to work toward opportunities for Moderna to research, develop and manufacture mRNA medicines in China."
The deal shows that Moderna is trying to take advantage of the success of its COVID-19 vaccine that has been used on people worldwide. The vaccine used a platform called mRNA to push human cells to make an immune response against a virus. At any rate, the agreement was sealed on Wednesday, and this is Moderna's very first deal with the Chinese government.
Photo by: Ian Hutchinson/Unsplash
